API | aclarubicin

aclarubicin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central MeSH PubChem

Active Ingredient History

NOW

Aclarubicin (INN) or aclacinomycin A is an anthracycline drug that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. It can induce histone eviction from chromatin upon intercalation. ^Wikipedia

Chemistry

SMILES: CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)c5c(O)c6C(=O)c7c(O)cccc7C(=O)c6cc5[C@H]1C(=O)OC
InChIKey: USZYSDMBJDPRIF-SVEJIMAYSA-N
Mol. Mass: 811.88
ALogP: 3.16 Partition coefficient
ChEMBL Molecule:
aclarubicin

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (30)

Research & Development (30)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (1)

Leukemia, Myeloid, Acute

Experimental Indications - Clinical Trial Phases 1-4 (10)

Drug Therapy (Phase 2/Phase 3)

Geriatrics (Phase 2)

Induction Chemotherapy (Phase 3)

Leukemia (Phase 2)

Leukemia, Myeloid, Acute (Phase 4)

Livedoid Vasculopathy (Phase 1)

Myelodysplastic Syndromes (Phase 2/Phase 3)

Neoplasms ()

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Recurrence (Phase 1/Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 19
# of Trial Organizations: 30

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue